n-10-89.pdf

us-irs-notices-n-10-89n-10-89.pdfGuidance

Preserve advance releases and the authoritative Internal Revenue Bulletin rendition; directory timestamps are file-publication metadata, not legal effective dates. HTML bulletins begin June 2003; earlier available issues require full PDF parsing.

This collection currently includes the publisher’s available advance-release directory. Historical bulletin renditions are discovered separately; an advance-release record alone does not certify the collection archive complete.

Part III - Administrative, Procedural, and Miscellaneous

REQUEST FOR COMMENTS REGARDING THE EXCISE TAX ON MEDICAL
DEVICES

Notice 2010-89

PURPOSE
This notice invites public comments regarding issues that should be addressed in
guidance implementing the new excise tax on medical devices imposed by section 4191
of the Internal Revenue Code (Code). Section 4191 was added by section 1405 of the
Health Care and Education Reconciliation Act of 2010, Pub. L. No. 111-152, 124 Stat.
1029, 1064-1065 (the Act), in conjunction with the Patient Protection and Affordable
Care Act, Pub. L. No. 111-148, 124 Stat. 119. The new excise tax applies to sales of
taxable medical devices after December 31, 2012.

BACKGROUND
Under Chapter 32 (Manufacturers Excise Taxes) of Subtitle D of the Code,
excise taxes are imposed on the sales of certain products by the manufacturer,
producer, or importer. The Act amended Chapter 32 to add section 4191, which
imposes an excise tax on the sale of any “taxable medical device” by the manufacturer,
producer, or importer of the device in an amount equal to 2.3 percent of the sale price.
Section 4191(b)(1) provides that, in general, a “taxable medical device” is any
device, as defined in section 201(h) of the Federal Food, Drug, & Cosmetic Act
(FFDCA), that is intended for humans. Section 201(h) of the FFDCA defines “device”
as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent,
or other similar or related article, including any component, part, or accessory, which is
(1) recognized in the official National Formulary, or the United States Pharmacopeia, or
any supplement to them, (2) intended for use in the diagnosis of disease or other
conditions, or in the cure, mitigation, treatment, or prevention of disease, or (3) intended
to affect the structure or any function of the body, and which does not achieve its
primary intended purposes through chemical action within or on the body and which is

2
not dependent upon being metabolized for the achievement of its primary intended
purposes.
Section 4191(b)(2) provides that the term “taxable medical device” does not
include eyeglasses, contact lenses, hearing aids, or “any other medical device
determined by the Secretary to be of a type which is generally purchased by the general
public at retail for individual use.”
Section 4221 exempts certain sales from tax imposed under Chapter 32. The
Act amended section 4221 to limit the exemptions for taxable medical device sales to
sales by the manufacturer, producer, or importer (1) for use by the purchaser for further
manufacture, or for resale by the purchaser to a second purchaser for use by such
second purchaser in further manufacture; or (2) for export, or for resale by the
purchaser to a second purchaser for export.

REQUEST FOR COMMENTS
The Internal Revenue Service and Treasury Department request comments on
issues that should be addressed in guidance implementing the excise tax on medical
devices. Comments are specifically requested on the exemption in section
4191(b)(2)(D) for any medical device “determined by the Secretary to be of a type which
is generally purchased by the general public at retail for individual use.” In addition,
comments are requested on issues pertaining to the application of existing Chapter 32
rules to section 4191. Comments must be submitted by March 3, 2011. Comments,
identified by Notice 2010-89, may be sent by one of the following methods:

o Mail:
Internal Revenue Service
CC:PA:LPD:PR (Notice 2010-89)
Room 5203
P.O. Box 7604
Ben Franklin Station
Washington, DC 20044

o Hand or courier delivery:
Submissions may be hand delivered Monday through Friday between the hours
of 8 a.m. and 4 p.m. to:
Courier's Desk
Internal Revenue Service
1111 Constitution Ave., N.W.
Washington, DC 20224
Attn: CC:PA:LPD:PR
(Notice 2010-89)

o Electronic:
Alternatively, taxpayers may submit comments electronically to
Notice.Comments@irscounsel.treas.gov. Please include “Notice 2010-89” in the
subject line of any electronic communications.

3
All submissions will be available for public inspection and copying in room 1621, 1111
Constitution Avenue, NW, Washington, DC, from 9 a.m. to 4 p.m.

DRAFTING INFORMATION
The principal author of this notice is Natalie A. Payne of the Office of Associate Chief
Counsel (Passthroughs & Special Industries Division). For further information regarding
this notice, please contact Ms. Payne or Stephanie Bland at (202) 622-3130 (not a toll-
free call).

Setzen Sie Ihre Recherche in ChatGPT oder Claude fort

Verbinden Sie Omnilex, um den Rechtskorpus über Ihren KI-Assistenten zu durchsuchen.